Researchers have announced that the rVSV-ZEBOV vaccine has shown 100 % effectiveness in a Phase III large-scale trial of over 7000 people in Guinea.
These results suggest that the efficacy of a single injection of rVSV-ZEBOV to prevent Ebola virus disease might be high, that protection can be established quickly, and that the vaccine might be effective at the population level when delivered by ring vaccination.